S&P 500
(0.12%) 5 303.27 points
Dow Jones
(0.34%) 40 004 points
Nasdaq
(-0.07%) 16 686 points
Oil
(0.97%) $80.00
Gas
(5.73%) $2.64
Gold
(1.44%) $2 419.80
Silver
(6.36%) $31.78
Platinum
(2.18%) $1 094.70
USD/EUR
(-0.02%) $0.920
USD/NOK
(-0.18%) $10.68
USD/GBP
(-0.27%) $0.787
USD/RUB
(0.19%) $91.05

Realtime updates for Candel Therapeutics, Inc. [CADL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
66.67%
return 18.22%
SELL
57.14%
return 1.56%
Last Updated17 May 2024 @ 16:00

-9.45% $ 11.50

BUY 1634 min ago

@ $11.45

Issued: 17 May 2024 @ 11:14


Return: 0.42%


Previous signal: May 17 - 09:30


Previous signal: Sell


Return: -12.98 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):
Our systems believe the stock currently is overvalued by 0.67% compare to its pairs and should correct downwards.
Profile picture for Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma...

Stats
Today's Volume 833 352
Average Volume 5.57M
Market Cap 342.06M
EPS $0 ( 2024-05-09 )
Next earnings date ( $0 ) 2024-08-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -8.78
ATR14 $2.10 (18.16%)
Insider Trading
Date Person Action Amount type
2024-01-12 Schoch Charles Sell 0 Common Stock
2024-01-12 Schoch Charles Sell 0 Common Stock
2024-01-12 Schoch Charles Sell 25 000 Stock Option (Right to Buy)
2024-01-12 Schoch Charles Sell 39 498 Stock Option (Right to Buy)
2023-11-28 Tyagarajan Seshu Sell 17 328 Common Stock
INSIDER POWER
76.85
Last 92 transactions
Buy: 8 106 969 | Sell: 4 393 086
Correlation (AI algo v.1.1b): Overvalued: -0.67% $11.47 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.58 (weak negative)
Short: 0.74 (moderate)
Signal:(50) Neutral

Candel Therapeutics, Inc. Correlation

10 Most Positive Correlations
SMTC0.955
MESO0.954
QRHC0.953
IZEA0.941
SCTL0.94
LE0.929
MOTNU0.923
USAP0.922
NN0.918
PAYS0.916
10 Most Negative Correlations
ATHN-0.936
PTRA-0.923
LINK-0.921
ARIZ-0.92
APDN-0.911
MBIO-0.905
AEY-0.902
HUGE-0.893
INTZ-0.89
ONEM-0.89

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Candel Therapeutics, Inc. Correlation - Currency/Commodity

The country flag -0.33
( neutral )
The country flag 0.38
( neutral )
The country flag 0.00
( neutral )
The country flag 0.09
( neutral )
The country flag -0.01
( neutral )
The country flag -0.76
( moderate negative )

Candel Therapeutics, Inc. Financials

Annual 2023
Revenue: $0
Gross Profit: $-1.20M (0.00 %)
EPS: $-1.310
FY 2023
Revenue: $0
Gross Profit: $-1.20M (0.00 %)
EPS: $-1.310
FY 2022
Revenue: $125 000
Gross Profit: $-862 000 (-689.60 %)
EPS: $-0.0994
FY 2021
Revenue: $0.00
Gross Profit: $0.00 (0.00 %)
EPS: $-1.934

Financial Reports:

No articles found.

Candel Therapeutics, Inc. Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators